Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Following peripheral administration, exenatide has been shown to suppress food intake via vagal-dependent and vagal-independent pathways that result in the direct activation of GLP-1R in the central nervous system
2025 saw a bidding war between Pfizer and Novo Nordisk for Metsera and its portfolio of obesity agents, which was ultimately won by Pfizer for up to $10 billion
In general, patients can expect the following progression: Weeks 1-4: During the first four weeks of treatment, patients typically experience a reduction in appetite and minimal weight loss
J Cell Physiol (2018) 233:642540
US$ 21.96
US$ 27.32
US$ 23.12
US$ 25.99
US$ 21.54
